rucaparib + rosuvastatin

Rucaparib + rosuvastatin is a non-fixed-dose combination of rucaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor for oncology indications, with rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor used for hypercholesterolemia and prevention of major cardiovascular events. This combination does not represent a marketed co-formulation, but is of pharmacological interest due to potential drug–drug interactions mediated by the inhibition of breast cancer resistance protein (BCRP) by rucaparib, which may modestly increase the exposure of rosuvastatin, a BCRP substrate. Clinical studies in patients with advanced solid tumors show weak pharmacokinetic interaction when both are coadministered, without a significant impact on safety or requirement for dose adjustment. Rucaparib's mechanism relates to inhibiting DNA repair in tumor cells, while rosuvastatin inhibits HMG-CoA reductase to lower cholesterol synthesis[1][2].